New book by Larry Connors Click here Improve your trading - See how
Merck said the shortages would not affect pediatric versions of the vaccine.
The Centers for Disease Control and Prevention said Merck competitor GlaxoSmithKline P.L.C. was producing enough hepatitis B vaccine to compensate for shortfalls.
Merck spokeswoman Amy Rose said the firm was not answering questions about what the upgrade included or whether it was planned.
"For competitive reasons, we'd prefer not to provide any details," she said. "This situation does not, in any way, impact the quality or safety of Recombivax HB now available on the market."
She could not say when Merck expected to meet demand again for the adult vaccine, sold as Recombivax HB, but she said it would be "in a timely manner."
Rose said the shortage was not related to an FDA warning in April that manufacturing practices at the Merck plant did not meet the agency's standards. The company has said those issues have been resolved.
Merck, which is based in Whitehouse Station, N.J., also has had shortages of its Zostavax shingles vaccine because of problems with the materials used to make it. That sent Zostavax's third-quarter sales down 82 percent to $11 million. Merck does not report sales for Recombivax.
Rose said the two shortages were unrelated. The company has said it hopes to eliminate back orders for Zostavax by the end of this year.
Doctors typically vaccinate children in the United States for hepatitis B, which can be transmitted through bodily fluids and attacks the liver. Adults get the vaccine only if they are at risk for exposure because of their jobs, lifestyle or travel.
Contact staff writer Miriam Hill at 215-854-5520 or hillmb@phillynews.com.
To see more of The Philadelphia Inquirer, or to subscribe to the newspaper, go to <a href=http://www.philly.com>http://www.philly.com</a>. Copyright (c) 2009, The Philadelphia Inquirer Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
